Clin. Cancer Res., 9: 1639 −1647, 2003

Total Page:16

File Type:pdf, Size:1020Kb

Clin. Cancer Res., 9: 1639 −1647, 2003 Tumors and Their Microenvironments: Tilling the Soil : Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639 −1647, 2003. Jonathan D. Cheng and Louis M. Weiner Clin Cancer Res 2003;9:1590-1595. Updated Version Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/9/5/1590 Cited Articles This article cites 45 articles, 17 of which you can access for free at: http://clincancerres.aacrjournals.org/content/9/5/1590.full.html#ref-list-1 Citing Articles This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/9/5/1590.full.html#related-urls E-mail alerts Sign up to receive free email-alerts related to this article or journal. Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Subscriptions Publications Department at [email protected]. Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected]. Downloaded from clincancerres.aacrjournals.org on November 12, 2012 Copyright © 2003 American Association for Cancer Research 1590 Vol. 9, 1590–1595, May 2003 Clinical Cancer Research The Biology Behind Tumors and Their Microenvironments: Tilling the Soil Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639–1647, 2003. Jonathan D. Cheng,1 and Louis M. Weiner “seminal influence” on the metastatic microenvironment, and Fox Chase Cancer Center, Department of Medical Oncology, thereby act together with the distant organ to effect tumor Philadelphia, Pennsylvania 19111 metastases. The identity of these seminal influences is a subject of active investigation but remains elusive. However, The Shifting Paradigm the importance of tumor-associated fibroblasts, the predom- The conventional concept of tumor-host interactions is inant cell in the microenvironment, has become more evident. rooted in the realm of parasitology. A tumor invades an unsus- pecting host, and in response to this assault, the host attempts to Tumor Stromal Fibroblasts: Contracted Farmers resist the advances of the tumor by calling on the armamentar- Both in vivo and in vitro studies have demonstrated that ium of the immune system. This implies a fundamental oppo- fibroblasts contribute to tumor formation and growth rates sition between the tumor and host in purpose and intent. How- (6), and can be thought of as “contracted farmers” used by ever, an accumulation of evidence points to an alternative tumors to prepare the microenvironment. Fibroblasts coin- paradigm, where the tumor microenvironment is not an idle oculated with breast or bladder tumor cell lines in nude mice bystander, but actively participates in tumor progression and shorten tumor latency and increase tumor growth (7). Fibro- metastasis (1, 2). In fact, stromal cells and their cytokines blasts cultured from malignant tumors have stimulatory ef- coordinate critical pathways that exert important roles in the fects on MCF-7 cells, whereas fibroblasts cultured from ability of tumors to invade and metastasize (3). normal tissue are inhibitory (8). Phenotypic differences In this issue, Scott et al. (4) describe a Phase I clinical trial among tumor-associated fibroblasts have also been seen. using the radiolabeled antibody sibrotuzumab to target the tu- Fibroblasts with smooth muscle differentiation, termed myo- mor stromal antigen FAP2 in metastatic lung and colon cancers. fibroblasts, are abundant in the stromal cells of malignant Human FAP is unique in its selective expression by tumor breast tissue but are rarely seen in normal breast tissue (9). stromal fibroblasts in epithelial carcinomas, but not by epithelial These findings suggest that tumor-associated fibroblasts are carcinoma cells, normal fibroblasts, or other normal tissues. functionally distinct compared with fibroblasts that are not in Therefore, FAP is an attractive target for the study of tumor the tumor microenvironment, and subpopulations of fibro- stromal cell biology and provides valuable insights into the roles blast may perform specialized functions to coordinate events of the tumor microenvironment. FAP may exemplify pathways required for tumor invasion and metastasis. Thus, fibroblasts by which the microenvironment soil is “tilled” in preparation for provide critical frameworks for tumor growth and metastasis. tumor invasion and metastasis. The microenvironment can also influence tumorigenic transformation. Kinzler and Vogelstein (10) proposed the The Tumor Microenvironment Soil concept of landscaper defects to explain the increased inci- The process of tumor metastasis was described using the dence of colorectal cancer in patients with juvenile polyposis “seed and soil” analogy by Paget (5) more than 100 years syndrome or ulcerative colitis. In this situation, the prolifer- ago. His landmark paper in 1889 examined 735 patients with ating stromal cells predispose the normal epithelial cells to breast cancer at autopsy and showed that the distribution of undergo malignant transformation. Thus, stromal inflamma- metastases did not occur by chance, but was regulated by the tion and proliferation eventually lead to the development of predisposition of congenial soil. For example, the liver had a malignant epithelial transformation because of an altered 14-fold higher incidence of metastases compared with the microenvironment terrain. Thus, the gene expression pattern spleen, although these organs roughly possess the same cir- of the fibrotic stroma is distinct from that of the carcinoma culatory volume. Paget (5) proposed that tumor cells, or cells. Iacobuzio-Donahue et al. (11, 12) used serial analysis “seeds,” were randomly scattered by vascular routes, but of gene expression techniques in breast cancer to show that could only form metastatic deposits if they landed in conge- five regions of invasive tumors can be identified, each with a nial territory, or “soil.” He hypothesized that tumors have a distinct gene expression profile. These regions consist of the neoplastic epithelium, angioendothelium, inflammatory stroma, panstroma, and juxtatumoral stroma. Furthermore, they identified receptor-ligand pairs between the neoplastic epithelium and the surrounding stroma, implying significant Received 3/25/03; accepted 3/28/03. communication between host and tumor compartments. In 1 To whom requests for reprints should be addressed, at Fox Chase addition, loss of heterozygosity has been identified in the Cancer Center, Department of Medical Oncology, 7701 Burholme Av- enue, Philadelphia, PA 19111. Phone: (215) 728-7083; Fax: (215) 728- fibrotic reaction surrounding pancreas cancer that is distinct 3639; E-mail: [email protected]. from the loss of heterozygosity pattern in pancreas adenocar- 2 The abbreviations used are: FAP, fibroblast activation protein. cinoma (13). A number of these genes identified in the Downloaded from clincancerres.aacrjournals.org on November 12, 2012 Copyright © 2003 American Association for Cancer Research Clinical Cancer Research 1591 stroma had not been associated previously with pancreatic ing wounds, can provide fertile soil for malignant cell “hom- adenocarcinoma. These studies imply that tumor stroma may ing.” Experimental animal models demonstrate that tumor me- contribute independently to tumor development through tastases arise preferentially in healing wounds (25, 26). The mutation-inducing phenotypes. Such considerations chal- incidence of wound recurrences is proportional to the extent of lenge preexisting notions of a passive stroma that is permis- wound trauma, as larger wounds and wounds that are not sur- sive of local tumor growth. gically repaired exhibit greater frequencies of metastasis. This has been confirmed clinically in the occurrences of surgical FAP: A Tractor wound and port site metastases (27, 28). Given the ability of the The current study by Scott et al. (4) demonstrates the wound healing environment to promote tumor cell proliferation ability to safely administer the humanized anti-FAP antibody (29), tumors may subvert normal wound healing machinery to sibrotuzumab to patients with FAP-positive malignancies with activate factors necessary for tumor metastases. Therefore, tu- tumor-specific uptake as seen by biodistribution images. This mor cells may initiate a permissive microenvironment by induc- clinical trial is an extension of the groundbreaking work by ing expression of permeability factors, procoagulants, or che- Garin-Chesa et al. in discovering the unique distribution of FAP motactic and mitogenic factors. on tumor stromal fibroblasts (14), and has been confirmed by Similarly, the fibrotic reaction seen in desmoplasia tends to Welt et al. (15) as a clinical target. FAP, also known as seprase confer a worse prognosis and may represent a histopathologic marker of fertilized soil. Invasive ductal carcinoma of the breast (16), is a Mr 95,000 cell surface glycoprotein expressed tran- siently in healing wounds, and abundantly on reactive stromal with a fibrotic focus has more aggressive clinical characteristics fibroblasts in Ͼ90% of human epithelial carcinomas (breast, than carcinoma without fibrosis (30, 31). The identification of lung, colorectal, and ovary; Ref. 14). Neural
Recommended publications
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers
    cancers Review Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers In-Hye Ham 1,2,† , Dagyeong Lee 1,3,† and Hoon Hur 1,2,3,* 1 Department of Surgery, Ajou University School of Medicine, Suwon 16499, Korea; [email protected] (I.-H.H.); [email protected] (D.L.) 2 Infamm-aging Translational Research Center, Ajou University School of Medicine, Suwon 16499, Korea 3 Department of Biomedical Science, Graduate School of Ajou University, Suwon 16499, Korea * Correspondence: [email protected]; Tel.: +82-31-219-5200; Fax: +82-31-219-5575 † These authors contributed equally to this work. Simple Summary: Gastrointestinal (GI) cancers are primary malignant tumors associated with cancer-related deaths worldwide. Although chemotherapy and radiotherapy are essential modalities to improve patient survival, many patients show resistance to these therapies. Various clinical studies have suggested that cancer-associated fibroblasts (CAFs) play a significant role in this resistance. In this review, we discuss CAF-produced cytokines, chemokines, growth factors, and exosomes, as well as desmoplastic reactions, all of which could be involved in cancer therapy resistance. In the future, the heterogeneity of CAFs should be considered such that CAF subtypes involved in cancer therapy resistance may be identified, thus improving the efficacy of chemotherapy and radiotherapy in GI cancers. Abstract: In the past few decades, the role of cancer-associated fibroblasts (CAFs) in resistance to Citation: Ham, I.-H.; Lee, D.; Hur, H. therapies for gastrointestinal (GI) cancers has emerged. Clinical studies focusing on GI cancers Cancer-Associated Fibroblast- have revealed that the high expression of CAF-related molecules within tumors is significantly Induced Resistance to Chemotherapy correlated with unfavorable therapeutic outcomes; however, the exact mechanisms whereby CAFs and Radiotherapy in Gastrointestinal enhance resistance to chemotherapy and radiotherapy in GI cancers remain unclear.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced Or Metastatic Fibroblast Activation Protein-Positive Cancer1
    Vol. 9, 1639–1647, May 2003 Clinical Cancer Research 1639 A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer1 Andrew M. Scott,2 Greg Wiseman, Sydney Welt, first 12 weeks of the study, with 24 patients being evaluable. Alex Adjei, Fook-Thean Lee, Wendie Hopkins, One patient received an additional 96 infusions on contin- Chaitan R. Divgi, Lorelei H. Hanson, ued-use phase for a total of 108 infusions over a 2-year period, and 1 patient received an additional 6 infusions on Paul Mitchell, Denise N. Gansen, continued use. There were no objective tumor responses. Steven M. Larson, James N. Ingle, Only one episode of dose-limiting toxicity was observed. Eric W. Hoffman, Paul Tanswell, Gerd Ritter, Therefore, a maximum tolerated dose was not reached. Leonard S. Cohen, Peter Bette, Lisa Arvay, Treatment-related adverse events were observed in 6 pa- Andree Amelsberg, Dan Vlock, tients during the infusional monitoring period. Four of the 6 Wolfgang J. Rettig, and Lloyd J. Old patients, 3 of whom had associated positive serum human antihuman antibody, were removed from the study because Ludwig Institute for Cancer Research, Melbourne Tumour Biology Austin, and Repatriation Medical Centre, Melbourne, 3084 Australia of clinical immune responses. Gamma camera images of [A. M. S., F-T. L., W. H., P. M.]; Mayo Clinic, Rochester, Minnesota [131I]sibrotuzumab demonstrated no normal organ uptake 55905 [G. W., A. Ad., L., H. H., D. N. G., J. N. I.]; Memorial Sloan of sibrotuzumab, with tumor uptake evident within 24–48 h Kettering Cancer Center, New York, New York 10021 [S.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
    US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel .
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
    Pure Appl. Chem., Vol. 84, No. 5, pp. 1113–1295, 2012. http://dx.doi.org/10.1351/PAC-REC-11-06-03 © 2012 IUPAC, Publication date (Web): 16 February 2012 IUPAC glossary of terms used in immunotoxicology (IUPAC Recommendations 2012)* Douglas M. Templeton1,‡, Michael Schwenk2, Reinhild Klein3, and John H. Duffus4 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; 2In den Kreuzäckern 16, Tübingen, Germany; 3Immunopathological Laboratory, Department of Internal Medicine II, Otfried-Müller-Strasse, Tübingen, Germany; 4The Edinburgh Centre for Toxicology, Edinburgh, Scotland, UK Abstract: The primary objective of this “Glossary of Terms Used in Immunotoxicology” is to give clear definitions for those who contribute to studies relevant to immunotoxicology but are not themselves immunologists. This applies especially to chemists who need to under- stand the literature of immunology without recourse to a multiplicity of other glossaries or dictionaries. The glossary includes terms related to basic and clinical immunology insofar as they are necessary for a self-contained document, and particularly terms related to diagnos- ing, measuring, and understanding effects of substances on the immune system. The glossary consists of about 1200 terms as primary alphabetical entries, and Annexes of common abbre- viations, examples of chemicals with known effects on the immune system, autoantibodies in autoimmune disease, and therapeutic agents used in autoimmune disease and cancer. The authors hope that among the groups who will find this glossary helpful, in addition to chemists, are toxicologists, pharmacologists, medical practitioners, risk assessors, and regu- latory authorities. In particular, it should facilitate the worldwide use of chemistry in relation to occupational and environmental risk assessment.
    [Show full text]